Drugs Made In America Acquisition Corp. Units (DMAAU) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition Corp. Units (DMAAU) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-125.18K could theoretically repay 0% of its total liabilities ($7.28 Million) in one year. See DMAAU free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition Corp. Units Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Drugs Made In America Acquisition Corp. Units across 2 annual periods. For the full cash flow conversion analysis, see DMAAU cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition Corp. Units (2024–2025)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition Corp. Units. Check Drugs Made In America Acquisition Corp. (DMAAU) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $795.67 | — |